FRANCE— Valerio Therapeutics S.A., a clinical-stage biotechnology company at the forefront of developing innovative DNA Decoy therapeutics, has announced its acquisition of Emglev Therapeutics, a spinoff from the prestigious Institut Curie, one of France’s leading cancer centers.
While the financial details of the transaction have not been disclosed, the acquisition is structured through a share sale involving cash and a contribution of Emglev shares in exchange for Valour Bio shares.
As a result, Emglev’s shareholders are now also stakeholders in Valour Bio, and this acquisition is expected to unlock new scientific and financial synergies within the Valerio Group.
Valerio Therapeutics and Valour Bio anticipate that the initial benefits from this strategic partnership will materialise in the first quarter of 2025.
In commenting on the acquisition, Dr. Shefali Agarwal, President and CEO of Valerio Therapeutics and CEO of Valour Bio, emphasised that the integration of Emglev Therapeutics through Valour Bio reinforces their commitment to delivering innovative therapeutics to patients in need.
Dr. Agarwal expressed enthusiasm for the potential advancements stemming from the next-generation technology developed by Emglev’s accomplished scientists.
She highlighted the prospect of yielding novel treatments, including sdAb drugs, radio-conjugates, bispecific T-cell engagers, and various sdAb-based therapies.
Dr. Agarwal elaborated on the promise of this platform, noting its versatility in targeting a broad array of antigens.
She believes it can potentially address some of the current limitations associated with antibody-based therapeutics, particularly regarding tissue penetration, immunogenicity, and manufacturing ease.
Following the acquisition, Valour Bio plans to concentrate on optimizing the therapeutic applications of single-domain antibodies.
It aims to develop treatments for severe and life-threatening conditions, including autoimmune diseases, inflammatory disorders, and cancers.
Echoing this sentiment, Christelle Masdeu expressed her excitement about the collaborative efforts between Emglev and Valerio Therapeutics.
As a shareholder of Valour Bio, which now oversees the Emglev platform, Masdeu reiterated her commitment to investing the team’s collective energy, expertise, and passion into developing unique treatments that address unmet medical needs.
She highlighted the synergy created by combining Emglev’s proprietary synthetic single-domain antibody platform with Valerio’s distinguished preclinical and clinical development capabilities, which aligns perfectly with their mission to deliver transformative therapies to improve patient outcomes.
Sign up to receive our email newsletters with the latest news updates and insights from Africa and the World HERE
